Overview
Location
Singapore
Employees
11-50
Total raised
$20M
Founded date
2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 15, 2025 | Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations | SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance ... |
| Feb 12, 2025 | Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma | SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a... |
| Jun 27, 2023 | SG biotech firm Lion TCR bags $40m funding from Chinese investors | Singapore-headquartered biotech company Lion TCR has raised $40 million in a Series B2 funding round led by state investor Guangzhou Industrial Investment and Capital Operation Holding Group, according to a company statement. |
| Jun 27, 2023 | Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy | SINGAPORE and GUANGZHOU, China, June 27, 2023 /PRNewswire/ -- 27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of its USD 40 million Series B2 financing round. Guangzho... |
| Sep 23, 2021 | Lion TCR Announces FDA IND Clearance for its LioCyx-M004 for Hepatocellular Carcinoma | SINGAPORE and Guangzhou, China and LOS ANGELES, Sept. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd, a clinical-stage biotech company specialized in T Cell Receptor (TCR) T cell therapy today announced that it has received clearance from U.S. F... |
| May 30, 2018 | Term Sheet — Wednesday, May 30 | 5 Qs WITH A DEALMAKER Melinda Gates needs no introduction. Paid Content You can't secure what you can't see From ExtraHop “I am a big believer in disruptive innovation, but it’s been incredibly disappointing to watch how few women... |
| May 29, 2018 | Biotech Company Lion TCR Raises US$20M in Series A Financing Round | Lion TCR Pte Ltd, a Singapore-based clinical stage biotech pioneering T cell therapy against viral- related cancer, raised US$20m in Series A financing round. The round was led by undisclosed existing investors and other new investors such ... |
| Lion TCR | “At Lion TCR, over a decade’s worth of basic research, product engineering and development, and pre-clinical/clinical assessment have culminated in our leading product that harnesses the power of a patient’s own immune system to eliminate H... |
Reviews 0
FAQ about Lion TCR
When was Lion TCR founded?
Lion TCR was founded in 2015.
How much funding has Lion TCR raised?
Lion TCR has raised $20M in total across 1 funding round.
What has the press written about Lion TCR?
Parsers VC has collected 9 articles mentioning Lion TCR, among them “Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations” (Sep 15, 2025) and “Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma” (Feb 12, 2025).
Is Lion TCR still active?
Yes, Lion TCR is active; its latest activity on Parsers VC dates from Nov 6, 2026.